ATE496621T1 - Imidazoä2,1-büthiazole und ihre verwendung als pharmazeutika - Google Patents

Imidazoä2,1-büthiazole und ihre verwendung als pharmazeutika

Info

Publication number
ATE496621T1
ATE496621T1 AT07819562T AT07819562T ATE496621T1 AT E496621 T1 ATE496621 T1 AT E496621T1 AT 07819562 T AT07819562 T AT 07819562T AT 07819562 T AT07819562 T AT 07819562T AT E496621 T1 ATE496621 T1 AT E496621T1
Authority
AT
Austria
Prior art keywords
formula
compounds
synthase
expression
endothelial
Prior art date
Application number
AT07819562T
Other languages
English (en)
Inventor
Gerhard Zoller
Hartmut Strobel
David Will
Paulus Wohlfart
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Application granted granted Critical
Publication of ATE496621T1 publication Critical patent/ATE496621T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT07819562T 2006-11-16 2007-11-03 Imidazoä2,1-büthiazole und ihre verwendung als pharmazeutika ATE496621T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06023790A EP1923062A1 (de) 2006-11-16 2006-11-16 Imidazo[2,1-b]thiazole und ihre Verwendung als Pharmazeutika
PCT/EP2007/009539 WO2008058641A1 (en) 2006-11-16 2007-11-03 Imidazo[2, 1-b]thiazoles and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
ATE496621T1 true ATE496621T1 (de) 2011-02-15

Family

ID=37875485

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07819562T ATE496621T1 (de) 2006-11-16 2007-11-03 Imidazoä2,1-büthiazole und ihre verwendung als pharmazeutika

Country Status (6)

Country Link
US (1) US8080569B2 (de)
EP (2) EP1923062A1 (de)
JP (1) JP5193217B2 (de)
AT (1) ATE496621T1 (de)
DE (1) DE602007012289D1 (de)
WO (1) WO2008058641A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2567959B1 (de) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
US20130085157A1 (en) * 2011-09-30 2013-04-04 Emilie D. Smith Arylsubstituted thiazolotriazoles and thiazoloimidazoles
WO2024076331A1 (en) * 2022-10-05 2024-04-11 Istanbul Universitesi Rektorlugu HYDRAZINECARBOTHIOAMIDE AND 1,2,4-TRIAZOLE-3-THION DERIVATIVE COMPOUNDS CARRYING IMIDAZO[2,1-b]THIAZOLE RING AND SYNTHESIS METHODS OF THESE COMPOUNDS

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180597B1 (en) 1998-03-19 2001-01-30 Brigham And Women's Hospital, Inc. Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
AU4990599A (en) 1998-07-14 2000-02-07 Brigham And Women's Hospital Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
TWI241190B (en) 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
PE20020870A1 (es) 2001-02-13 2002-11-18 Aventis Pharma Gmbh 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
PE20020856A1 (es) 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-tetrahidronaftil aminas aciladas
EP1388535A1 (de) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylierte Arylcycloalkylamine und ihre Anwendung als Arzneimittelwirkstoff
EP1388341A1 (de) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Substituierte Acylamino heteroaromatische Verbindungen und ihre Verwendung als Arztneimittel
EP1388342A1 (de) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylierte, Heteroaryl-kondensierte Cycloalkenylamine und deren Verwendung als Arzneimittel
EP1471066A1 (de) 2003-04-24 2004-10-27 Aventis Pharma Deutschland GmbH Triaza- und Tetraaza-anthrazendionderivate, ihre Herstellung und Verwendung als Pharmazeutika
GB0416396D0 (en) * 2004-07-22 2004-08-25 Angeletti P Ist Richerche Bio Therapeutic agents
TW200639177A (en) * 2005-02-08 2006-11-16 Prosidion Ltd Dihydroimidazothiazole derivatives
WO2007039146A1 (en) * 2005-09-23 2007-04-12 Smithkline Beecham Corporation 4-carboxy pyrazole derivatives as anti-viral agents

Also Published As

Publication number Publication date
EP1923062A1 (de) 2008-05-21
JP5193217B2 (ja) 2013-05-08
EP2086537B1 (de) 2011-01-26
EP2086537A1 (de) 2009-08-12
WO2008058641A1 (en) 2008-05-22
US20100004299A1 (en) 2010-01-07
JP2010510182A (ja) 2010-04-02
DE602007012289D1 (de) 2011-03-10
US8080569B2 (en) 2011-12-20

Similar Documents

Publication Publication Date Title
ATE554765T1 (de) Imidazoä1,2-aüpyridine und ihre verwendung als arzneimittel
WO2008074413A3 (en) Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial no synthase
TW200800941A (en) Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals
BR0313294A (pt) Compostos heteroaromáticos substituìdos com acilamino e seu uso como substâncias farmacêuticas
RS20050097A (en) Acylated,heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
RS20050098A (en) Acylated arylcycloalkylamines and their use as pharmaceutica ls
EA200602191A1 (ru) 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
NO20056010L (no) Biaryloksymetylaren-karboksylsyrer
WO2007011833A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
MY148937A (en) Medicaments with hm74a receptor activity
NO20084845L (no) 2-pyrazinonderivater for behandling av sykdom eller tilstander der inhibiering av neutrofil elastaseaktivitetet er gunstig
BR0310106A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
CY1111086T1 (el) Παραγωγα 2-αμινο-κιναζολινης χρησιμα ως αναστολεις της βητα-σεκρετασης (bace)
NO20083710L (no) Dihydrotienopyrimidin for behandling av betennelsesforstyrrelser
NO20084872L (no) 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig
BRPI0410466A (pt) derivados de indol como inibidores de fator xa
NO20064951L (no) 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse
WO2008054698A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006055434A3 (en) Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease
CN102985553A (zh) 沉默调节蛋白活化剂和活化测定
ATE507226T1 (de) 1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung
ATE357453T1 (de) Comt-inhibitoren
ATE496621T1 (de) Imidazoä2,1-büthiazole und ihre verwendung als pharmazeutika
MXPA05011267A (es) Derivados de la triaza-y tetraaza-antracenodiona, su preparacion y su uso como productos farmaceuticos.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties